Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Behind-the-counter statins: a silver bullet for reducing costs and increasing access?

Sood N, Sun E, Zhuo X.

Health Serv Res. 2012 Feb;47(1 Pt 1):174-87. doi: 10.1111/j.1475-6773.2011.01315.x. Epub 2011 Aug 30.

2.

Over-the-counter statins.

Malik NN.

Lancet. 2004 Jul 31-Aug 6;364(9432):411. No abstract available.

PMID:
15288726
3.

Comparison of prescription drug costs in the United States and the United Kingdom, Part 1: statins.

Jick H, Wilson A, Wiggins P, Chamberlin DP.

Pharmacotherapy. 2012 Jan;32(1):1-6. doi: 10.1002/PHAR.1005.

PMID:
22392823
4.

Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.

Godman B, Bishop I, Campbell SM, Malmström RE, Truter I.

Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):323-30. doi: 10.1586/14737167.2015.967221. Epub 2014 Oct 23.

PMID:
25338546
5.

The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013.

Fuksa L, Vocelka M, Vytrisalova M.

Health Policy. 2015 Sep;119(9):1255-64. doi: 10.1016/j.healthpol.2015.02.016. Epub 2015 Mar 24.

PMID:
25929214
6.

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.

McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):73-85. doi: 10.1586/erp.09.73.

PMID:
20121565
7.

Switching statins: cost of simvastatin is overestimated.

Ashcroft JS.

BMJ. 2006 Jun 24;332(7556):1512. No abstract available.

8.

On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate.

Macchia A, Mariani J, Romero M, Robusto F, Lepore V, Dettorre A, Tognoni G.

Eur J Clin Pharmacol. 2015 Apr;71(4):449-59. doi: 10.1007/s00228-015-1808-0. Epub 2015 Feb 11.

PMID:
25666028
9.

Statin prescribing fell after drug became available over the counter.

Dobson R.

BMJ. 2006 Sep 16;333(7568):569. No abstract available.

10.

Integrating economic analysis into clinical trials.

Imai K, Zhang P.

Lancet. 2005 May 21-27;365(9473):1749-50. No abstract available.

PMID:
15910936
11.

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.

Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R; Heart Protection Study Collaborative Group..

Lancet. 2005 May 21-27;365(9473):1779-85.

PMID:
15910950
12.

The value of atorvastatin over the product life cycle in the United States.

Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD.

Clin Ther. 2011 Oct;33(10):1433-43. doi: 10.1016/j.clinthera.2011.08.014. Epub 2011 Sep 28.

PMID:
21955936
13.

Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.

Devold HM, Molden E, Skurtveit S, Furu K.

Br J Clin Pharmacol. 2009 Feb;67(2):234-41. doi: 10.1111/j.1365-2125.2008.03345.x. Epub 2009 Feb 9.

14.
15.

Drug use review matters.

Mueting M.

Nebr Nurse. 2007 Sep-Nov;40(3):28. No abstract available.

PMID:
17915614
16.
17.

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).

Smith DG, McBurney CR.

Pharmacoeconomics. 2003;21 Suppl 1:13-23.

PMID:
12648031
18.

Statin cost-effectiveness in the United States for people at different vascular risk levels.

Heart Protection Study Collaborative Group..

Circ Cardiovasc Qual Outcomes. 2009 Mar;2(2):65-72. doi: 10.1161/CIRCOUTCOMES.108.808469. Epub 2009 Mar 5.

19.

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.

Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P.

Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):475-84. doi: 10.1586/erp.09.43.

PMID:
19817531
20.

The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database.

Filion KB, Delaney JA, Brophy JM, Ernst P, Suissa S.

Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):1-4.

PMID:
16953516

Supplemental Content

Support Center